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Abstract 
Although promising preliminary results have been widely observed with 
bevacizumab for recurrent malignant gliomas, many unanswered questions remain to be 
resolved to achieve an optimal outcome. No predictive biomarkers of a survival benefit 
from bevacizumab have been established, and no consensus exists about the response or 
survival benefit regarding the prior recurrence pattern or tumor location. Here we 
retrospectively analyzed the clinical benefit from bevacizumab for recurrent malignant 
gliomas in relation to the prior recurrence pattern or tumor location. Thirty-one 
consecutive patients with recurrent malignant gliomas who were treated with 
bevacizumab were investigated. The treatment response and survival benefit from 
bevacizumab were analyzed in association with age, sex, Karnofsky performance status, 
prior pathological diagnosis, prior recurrence pattern, primary location of tumor, 
recurrence status, and expression of angiogenic and hypoxic markers. The group with 
leptomeningeal dissemination had a significantly shorter median overall survival with 
bevacizumab (OSBev) (6.0 months, 95% confidence interval (CI) 1.4-10.7) compared to 
those in the local/distant group (11.8 months, 95% CI 6.1-17.4). The median OSBev of 
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the infratentorial tumor group and supratentorial tumor group were 9.2 months (95% CI 
5.0-13.4) and 10.4 months (95% CI 6.6-14.3), respectively. With multivariate analysis, 
the prior recurrence pattern was the only independent prognostic factor of OSBev. 
Patients with leptomeningeal dissemination of recurrent malignant glioma experienced 
minimal benefit from bevacizumab. Therefore, in the context of cost effectiveness, 
bevacizumab is not recommended for patients with leptomeningeal dissemination. 
 
Keywords: bevacizumab, efficacy, prior recurrence pattern, tumor location 
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Introduction 
Malignant gliomas are the most common and aggressive type of primary brain 
tumor, and the prognosis is generally extremely poor. Despite advances in standard 
therapy, including surgery, radiotherapy, and chemotherapy, recurrence is almost 
inevitable after a median survival time of 8-9 months[1]. However, current treatment 
options for patients with recurrent malignant gliomas are limited and are selected on a 
case-by-case basis due to the absence of established standard therapy. Consequently, 
survival outcomes for recurrent malignant gliomas are dismal, with a median survival of 
25–40 weeks[2-4]. 
Bevacizumab, a humanized monoclonal antibody that inhibits vascular endothelial 
growth factor (VEGF), is an antiangiogenic drug used to treat recurrent malignant 
gliomas. Several phase II studies have demonstrated significant radiographic response 
rates and improved 6-month progression-free survival in patients with recurrent 
malignant gliomas who were treated with single-agent bevacizumab[2, 5, 6]. Despite 
these promising results, many unanswered questions remain to be resolved to achieve an 
optimal outcome. The most crucial issue is that only a subset of patients who receive 
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bevacizumab obtain a clinical benefit[7]. To date, despite extensive efforts aimed at 
biomarker discovery using tumor tissue or blood samples, no predictive biomarkers of 
survival benefit from bevacizumab for malignant gliomas have been established [7-10]. 
A few reports investigating the response or survival benefit from bevacizumab have 
focused on the prior recurrence pattern or tumor location[11-14]. A clinically significant 
question is whether patients with leptomeningeal dissemination of recurrent malignant 
gliomas or patients with recurrent malignant gliomas located in the posterior fossa 
including the brainstem and cerebellum can obtain some clinical benefit from 
bevacizumab. In this study, we retrospectively analyzed the clinical benefit from 
bevacizumab for recurrent malignant gliomas regarding the prior recurrence pattern and 
tumor location. 
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Materials and Methods 
We investigated 31 consecutive patients with recurrent malignant gliomas who 
were treated with bevacizumab at the University of Tsukuba Hospital between June 
2013 and June 2016. Recurrence was radiologically confirmed according to the 
response assessment criteria (RANO) for high-grade gliomas[15]. All patients had 
received radiotherapy and temozolomide, except for one patient with pontine glioma 
who received radiotherapy and etoposide. All patients received bevacizumab at a dose 
of 10 mg/kg intravenously every other week. Treatment response to bevacizumab 
therapy was assessed according to the RANO criteria.  
Immunohistochemical analysis of surgical specimens of the original tumors was 
performed to evaluate VEGF-A, VEGFR-2, and Hypoxia-inducible factor 1α (HIF-1α) 
protein expression[16]. Briefly, the specimen was fixed in 10% formalin and embedded 
in paraffin. Histologic sections, 2 mm in thickness, were deparaffinized in xylene and 
incubated with rabbit polyclonal anti-VEGF-A antibody (A-20, Santa Cruz), rabbit 
polyclonal anti-VEGFR-2 antibody (Phospho-Tyr1214, Signalway antibody), or mouse 
monoclonal anti-HIF-1α antibody (H1alpha67, Novus Biologicals). The DAKO LSAB 
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2 kit was used to visualize VEGF-A and VEGFR-2, and the DAKO CSA II system was 
used to visualize HIF-1α. Expression of VEGF-A, VEGFR-2, and HIF-1α was 
determined by semiquantitative assessment of the proportion of positively stained tumor 
cells. Cases with ≥10% positive cells were rated as positive, whereas cases with <10% 
positive cells were rated as negative. 
Statistical analyses were performed using SPSS software (version 22; SPSS, Inc.). 
Overall survival with bevacizumab (OSBev), defined as the time from start of 
bevacizumab until death, was used to investigate the prognostic value of the analyzed 
variables. Survival probabilities were calculated using the Kaplan-Meier method, and 
differences among patient groups were evaluated using the log-rank test. The following 
prognostic factors were analyzed: age (<60 years vs. ≥60 years), sex (male vs. female), 
Karnofsky performance status (KPS) (<50 vs. ≥50), prior pathological diagnosis 
(glioblastoma vs. others), prior recurrence pattern (leptomeningeal dissemination vs. 
local/distant), primary location of tumor (infratentorial vs. supratentorial), recurrence 
status (first vs. second/third), VEGF-A expression (negative vs. positive), VEGFR-2 
expression (negative vs. positive), and HIF-1α expression (negative vs. positive). 
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Factors with a probability value of less than 0.1 on univariate analysis were selected for 
testing in the multivariate analysis using the Cox proportional hazards model. Results 
are expressed as relative risk and the 95% confidence interval (CI).  
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Results  
The baseline characteristics of the 31 patients are shown in Table 1. The mean age 
of the patients was 52.5 years (range, 6-78). Fifteen patients were males and 16 were 
females. Of the 31 patients, 22 had glioblastoma, five had anaplastic astrocytoma 
pathologically diagnosed at the first or second operation prior to bevacizumab therapy, 
and four had no pathological diagnosis because the tumor was located in the pons or 
medulla oblongata. primary locations of tumor were supratentorial (n = 23), cerebellum 
(n = 3), midbrain (n = 1), pons (n = 2), and medulla oblongata (n = 2). Twenty-five of 
the 31 patients developed local or distant recurrences, whereas six patients recurred with 
leptomeningeal dissemination. Eighteen patients received bevacizumab therapy 
primarily as the second line therapy, 10 as the third line, and three as the fourth line. 
Neither patient had undergone re-resection of recurrent tumor immediately before the 
administration of bevacizumab. The median KPS was 60 (30-90). 
According to the RANO criteria, 19 patients (61.3%) had a partial response, eight 
(25.8%) had stable disease, and four (12.9%) had progressive disease; the objective 
response rate was 87.0%. Seven patients were alive at the time of analysis, with a mean 
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follow–up time of 5.5 (range, 2.4-10.4) months. The median OSBev for all patients was 
9.3 months (95% CI, 6.3-12.2). The results of univariate analysis based on the 
Kaplan-Meier method and the log-rank test are shown in Fig. 1. The prior recurrence 
pattern was significantly associated with OSBev. The leptomeningeal dissemination 
group had a significantly shorter median OSBev (6.0 months, 95% CI 1.4-10.7) 
compared to those with local/distant recurrence (11.8 months, 95% CI 6.1-17.4). The 
primary location of tumor was not associated with OSBev. The median OSBev of the 
infratentorial tumor group and supratentorial tumor group were 9.2 months (95% CI 
5.0-13.4) and 10.4 months (95% CI 6.6-14.3), respectively. We found no statistically 
significant difference in OSBev according to recurrence status (second/third vs. first). 
The median OSBev of the second/third recurrence group and first recurrence group were 
10.4 months (95% CI 7.5-13.3) and 9.2 months (95% CI 6.5-11.9), respectively. 
Univariate and multivariate analyses of the prognostic factors are summarized in Tables 
2 and 3, respectively. Univariate analysis of other factors showed that sex, VEGF-A 
expression, and VEGFR-2 expression were significant factors associated with OSBev. 
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Multivariate analysis showed that the prior recurrence pattern was the only independent 
prognostic factor of OSBev. 
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Discussion 
In the present study, we analyzed the association between multiple factors including 
the prior recurrence pattern and primary location of tumor, and the clinical benefit from 
bevacizumab for recurrent malignant gliomas. Leptomeningeal dissemination as a 
recurrence pattern was significantly associated with poor OSBev. On the other hand, 
OSBev of the infratentorial tumor group was almost the same as that of the supratentorial 
tumor group. 
Parsa et al. reported that the median survival time from the date of documented 
dissemination to death of 92 patients with tumor dissemination who were treated 
without bevacizumab was 23 weeks, which was almost equal to those treated with 
bevacizumab in the present study[17]. To the best of our knowledge, no clinical studies 
have investigated the association between the efficacy of bevacizumab therapy and the 
prior recurrence pattern, particularly regarding leptomeningeal dissemination. Only two 
case reports have been described. Fiorentino et al. reported a case of recurrent 
glioblastoma with leptomeningeal and intramedullary dissemination that was treated 
with bevacizumab and palliative radiotherapy[18]. After six cycles of bevacizumab 
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administration, progression of the intracranial mass was detected on magnetic resonance 
imaging, and no improvement was documented. Okita et al. described a case of 
recurrent glioblastoma with leptomeningeal dissemination that was treated with 
bevacizumab and temozolomide[13]. Although transient neurological and radiological 
improvement was observed, progression of the leptomeningeal dissemination occurred, 
and the patient became bedridden after five cycles of bevacizumab administration. Our 
results in the present study are consistent with these previous case reports and suggest 
that bevacizumab does not offer any clinical benefit for patients with recurrent 
malignant glioma with leptomeningeal dissemination. 
Regarding the clinical potential of bevacizumab for infratentorial recurrent 
malignant gliomas, only limited reports have been published so far. Reithmeier et al. 
reported a case series of three patients with progressive brainstem gliomas treated with 
bevacizumab[14]. The authors mentioned improvement in the clinical condition and 
reduction in amino acid uptake in the tumor area, and thus, they suggested that 
bevacizumab may represent a therapeutic salvage option for recurrent brainstem 
gliomas. On the other hand, Gururangan et al. demonstrated only minimal efficacy with 
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bevacizumab treatment plus CPT-11 in pediatric patients with recurrent brainstem 
gliomas[11]. Thus, the clinical potential for bevacizumab for recurrent brainstem 
gliomas remains controversial. Moreover, to the best of our knowledge, no reports have 
focused on the association between the efficacy of bevacizumab and malignant gliomas 
located in the cerebellum. In the present study, the objective response rates of the 
infratentorial tumor group and the supratentorial group were 75.0% and 91.3%, 
respectively. Likewise, we found no statistically significant difference between OSBev of 
the infratentorial tumor group and that of the supratentorial group. Because of the 
difference in tumor characteristics including the pathological diagnosis between the two 
groups, we cannot conclude that the efficacy of bevacizumab for infratentorial recurrent 
malignant gliomas is comparable to that for supratentorial recurrent malignant gliomas. 
However, we showed that some patients in both the infratentorial tumor group and the 
supratentorial group responded to bevacizumab therapy.  
The optimal timing for beginning bevacizumab therapy for recurrent malignant 
gliomas is a clinically relevant concern. In the present study, no significant difference in 
OSBev according to the recurrence status (second/third vs. first) was identified. Our 
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results were consistent with a previous report that focused on the timing for starting 
bevacizumab therapy (early or later recurrence)[19]. Piccioni et al. demonstrated that 
survival time after bevacizumab therapy is similar at each recurrence and suggested that 
efficacy of bevacizumab is fixed whether given early or late. Based on our findings and 
those of others of the equivalent efficacy of bevacizumab according to recurrence status, 
the treatment strategy of using bevacizumab as a therapy of last resort may be a 
preferable option for recurrent malignant gliomas. 
Immunohistochemical analysis of angiogenic and hypoxic markers on surgical 
specimens of the original tumors in the present study only showed a trend toward a 
positive association between angiogenic markers and prolonged survival but not 
between hypoxic markers and prolonged survival. Although the expression of VEGF-A 
and VEGFR-2 was significantly correlated with prolonged OSBev in univariate analysis, 
this correlation did not reach statistical significance in multivariate analysis. 
Sathornsumetee et al. reported that high VEGF expression in tumors is correlated with 
an increased likelihood of a radiographic response to bevacizumab therapy but not 
increased survival[7]. Similarly, in other studies of solid cancers, only weak and 
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restricted predictive values of VEGF expression in the primary tumor specimen were 
reported[20]. Despite the proof-of-concept of antiangiogenic therapy targeting VEGF, 
expression of angiogenic and hypoxic markers in tumor specimens does not sufficiently 
predict survival. 
In conclusion, we demonstrated that patients with leptomeningeal dissemination of 
recurrent malignant gliomas experience minimal benefit from bevacizumab. Therefore, 
in terms of cost effectiveness, bevacizumab is not recommended for patients with 
leptomeningeal dissemination. We also demonstrated that a subset of patients with 
recurrent malignant gliomas located in the posterior fossa experienced some clinical 
benefit from bevacizumab. Further studies with a larger number of patients are needed 
to validate our current results and to identify the patient populations with infratentorial 
gliomas as well as supratentorial gliomas who are likely to experience a benefit from 
bevacizumab.  
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Figure Captions 
Fig. 1: The results of univariate analysis based on the Kaplan-Meier method 
A: Kaplan-Meier estimates of overall survival with bevacizumab according to the prior 
recurrence pattern (dissemination vs. local/distant). B: Kaplan-Meier estimates of 
overall survival with bevacizumab according to tumor location (infratentorial vs. 
supratentorial). C: Kaplan-Meier estimates of overall survival with bevacizumab 
according to recurrence status (second/third vs. first).  
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Table 1
Patient Characteristics
Characteristics No. of patients %
Age (yrs)
 Mean ± SD
  Range
52.5 ± 19.1 
6-78
Gender
 Male 15 48.4
 Female 16 51.6
Prior pathological diagnosis
 glioblastoma 22 71.0
 anaplastic astrocytoma 5 16.1
 N.A (pons, medulla) 4 12.9
Primary Location of tumor
 supratentorial 23 74.2
  infratentorial 8 25.8
Recurrence pattern
 Local/Distant 25 80.6
 Dissemination 6 19.4
Recurrence status
 First 18 58.1
 Second 10 32.2
 Third 3 9.7
KPS
 90 2 6.5
 80 2 6.5
 70 3 9.7
 60 12 38.7
 50 8 25.8
 40 2 6.5
 30 2 6.5
SD: standard deviation, KPS: Karnofsky performance status
Table 2
Univariate analysis
Variable Hazard ratio (96% CI) p Value
Age ( <60 yrs vs. ≥60 yrs) 2.271 (0.872-5.913) 0.093
Gender (male vs. female) 2.833 (1.072-7.484) 0.036
Prior pathological diagnosis (glioblastoma vs. others) 1.126 (0.429-2.959) 0.810
Recurrence pattern (dissemination vs. local/distant) 48.162 (5.402-429.366) 0.001
Primary Location of tumor (infratentorial vs. supratentorial) 1.229 (0.449-3.364) 0.688
Recurrence status (first vs. second/third) 1.138 (0.496-2.611) 0.760
Karnofsky performance status  ( <50 vs. ≥50) 1.420 (0.412-4.894) 0.578
VEGF-A (negative vs. positive) 4.477 (1.366-14.670) 0.013
VEGFR-2 (negative vs. positive) 4.031 (1.180-13.764) 0.026
HIF-1α (negative vs. positive) 1.822 (0.223-14.899) 0.576
Table 3
Multivariate analysis
Variable Hazard ratio (96% CI) p Value
Age ( <60 yrs vs. ≥60 yrs) 1.113 (0.224-5.538) 0.896
Gender (male vs. female) 1.113 (0.245-5.064) 0.889
Recurrence pattern (dissemination vs. local/distant) 24.637 (1.873-324.047) 0.015
VEGF-A (negative vs. positive) 3.855 (0.874-16.997) 0.075
VEGFR-2 (negative vs. positive) 2.193 (0.367-13.109) 0.389

